Swedish Orphan Biovitrum AB (Sobi) has jumped on the mergers and acquisition merry-go-round to acquire Dova Pharmaceuticals Inc., expanding its hematology franchise and commercial presence in the US.
Described by CEO Guido Oelkers as "a marriage made in heaven," the acquisition gives Sobi control of Dova ’s oral...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?